Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

L. Horn, J. G. Whisenant, H. Wakelee, K. L. Reckamp, H. Qiao, L. Du, J. Hernandez, V. Huang, S. N. Waqar, S. Patel, R. E. Sanborn, T. Shaffer, K. Garg, A. Holzhausen, K. Harrow, C. Liang, L. P. Lim, M. Li, C. M. Lovly

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)ii48
JournalAnnals of Oncology
StatePublished - Apr 2019

Cite this